News

Novartis announced the initiation of Phase III trials for ligelizumab (QGE031) - a high-affinity monoclonal anti-IgE antibody - in chronic spontaneous urticaria (CSU) patients whose…
Read More...

Evotec AG announced a new integrated drug discovery alliance with LEO Pharma, a global leader in medical dermatology. The collaboration goal is to generate new leads against innovative…
Read More...

Swedish life science company, OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development…
Read More...

Changzhou Qianhong Bio-pharma Co., Ltd. started construction of the phase two of pharmaceuticals production facility at Changzhou National Hi-Tech District on November 28. With an…
Read More...

Pluristem Therapeutics announced that it has entered into a license agreement with a subsidiary of Chart Industries, Inc. regarding Pluristem’s thawing device for cell-based therapies.…
Read More...

Revance Therapeutics announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., (Fosun Pharma Industrial), a…
Read More...

Sartorius Stedim Biotech (SSB), a leading international supplier of the biopharmaceutical industry, through its China affiliate, and Beijing-based Immunochina Pharmaceuticals, announced…
Read More...

Scientist.com and Allele Biotechnology & Pharmaceuticals have partnered to develop nanoantibodies for therapeutic applications. Experts selected through Scientist.com’s Genius…
Read More...

Novartis announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for AVXS-101, now known as ZOLGENSMA (onasemnogene…
Read More...

UCB announced that it has received an Import Drug License (IDL) from the National Drug Administration of China (CNDA), creating a pathway to make VIMPAT (lacosamide) available to treat…
Read More...

IQVIA announced that Napo Pharmaceuticals, Inc. (Napo), a wholly-owned subsidiary of Jaguar Health, Inc., has selected Orchestrated Customer Engagement (OCE), IQVIA Technologies’…
Read More...

Autolus Therapeutics plc announced that the first patient has been dosed in its Phase 1/2 LibrA T1 clinical trial of AUTO4, a developmental therapy for the treatment of relapsed or…
Read More...

Merck announced that the European Commission has approved DELSTRIGO and PIFELTRO for the treatment of HIV-1 infection. DELSTRIGO is a new once-daily fixed-dose combination tablet of…
Read More...

AbCellera announced its collaboration with Autolus Therapeutics plc (Autolus), a clinical stage biopharmaceutical company developing next-generation programmed T cell therapies. Under…
Read More...

Telix Pharmaceuticals Limited and Nihon Medi-Physics Co., Ltd. have announced that they have signed a collaboration agreement to jointly evaluate the feasibility of 225Ac-labeled…
Read More...

Coeptis Pharmaceuticals announced that it has entered into a binding agreement to acquire all outstanding shares of Elto Pharma, Inc. Elto Phama is developing eltoprazine, a…
Read More...

TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and I-Mab Biopharma…
Read More...

Ajinomoto Bio-Pharma Services presented data at the World ADC Summit in San Diego this month describing a proprietary site-selective bioconjugation technology, AJICAP. The AJICAP…
Read More...

The U.S. Food and Drug Administration approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune…
Read More...

Generex Biotechnology Corporation announced the signing of a Letter of Intent to acquire 51 percent of Olaregen Therapeutix Inc., a New York based regenerative medicine company. Generex…
Read More...